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Abstract
Purpose: Our previous study suggested that some pulmonary artery (PA) dosimetric parameters were associated
with mortality in unresectable non-small cell lung cancer (NSCLC) treated with definitive radiotherapy. The present
study aims to analyze the impact of both PA and heart dosimetric parameters on survival of patients with NSCLC
treated with definitive conventional fractionated radiotherapy (CFRT) in another independent research center and
further determine whether the PA should be considered a dose-limiting organ at risk (OAR) for patients receiving
thoracic CFRT.
Methods: We performed a retrospective analysis of successive patients with medically inoperable or unresectable
NSCLC treated with definitive radiotherapy or chemoradiotherapy from August 2010 to September 2014. Clinical
and pathological information, PA and heart dosimetric factors, and follow-up data were collected from each patient’s
records and evaluated as potential prognostic factors for survival. Survival probabilities were estimated by the Kaplan-
Meier method and compared by the log rank test. Cox proportional hazards regression models were performed to
determine the independent predicators of survival. The optimal cutoff points of continuous dosimetric variables were
determined by Youden index in receiver operating characteristic (ROC) analysis.
Results: This study analyzed the records of 141 patients, 50.4% had adenocarcinoma, 71.6% had stage III disease,
and 55% patients received concurrent chemoradiotherapy. Radiation dose ranged from 60 to 76 Gy in 30–38 fractions.
Median follow up was 16.9 months. Median overall survival (OS) was 20.5 months (95% confidence interval
[CI] 10.3-30.7 months), and 1-, 2-, 3-year OS rates were 75.2%, 58.2% and 56%, respectively. Univariate and
multivariate analysis showed that Karnofsky Performance Status (KPS) score, Charlson’s Comorbidity Index
(CCI), T and N stage, PA invasion grade and the percentage of PA volume that received 40 to 55 Gy (PA V40-55) were
significantly associated with OS. No significant associations were found between heart dosimetric factors
and OS. Median OS of patients with PA invasion grade 0, 1, 2, and 3 were 41.8, 27.8, 12.7 and 7.5 months,
respectively (P < 0.001). PA V40, V45, V50 and V55, using thresholds of 80%, 68%, 45%, and 32%, respectively,
were independent predictors for OS.
Conclusions: PA invasion grade and PA V40-55 appear associated with OS in patients with NSCLC treated
with definitive CFRT. We propose that PA be considered as a dose-limiting OAR for such patients.
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Background
Lung cancer is one of the most common cancers world-
wide, and non-small cell lung cancer (NSCLC) comprises
85% of lung cancer cases [1]. Radiotherapy is the primary
method of treating patients with medically inoperable or
unresectable locally advanced NSCLC (LA-NSCLC) [2–4];
addition of concurrent chemotherapy to radiotherapy
(CRT), which is standard care for unresectable LA-NSCLC,
achieves a median OS of 17–27 months [5–8]. Never-
theless, some patients suffer early recurrence and
severe adverse events, such as radiation-induced pulmonary
and esophageal injury, as well as massive hemoptysis.
Optimizing the radiation plan and minimizing radiation-
induced toxicities requires limiting the dose to the organs
at risk (OAR). Dose-volume parameters of lung, such as
V20 and mean lung dose (MLD), are known to play an
important role in predicting severe radiation pneumonitis
and early deaths [9]. The pulmonary artery (PA) is the most
commonly tumor-involved thoracic great vessel [10, 11].
Patients who had PA invasion by tumor were usually
considered to have unresectable disease, though vascular
reconstruction has been applied in selected patients. Our
previous study of 100 patients with inoperable NSCLC in
the United State first categorized the grade of PA invasion
by contrast-enhance Computed Tomography (CT) or Posi-
tron Emission Tomography (PET) scan and indicated that
only 2 out of 4 patients with grade 5 PA invasion experi-
enced massive bleeding caused death, and overall grades of
PA invasion were not associated with overall survival in
patients with inoperable NSCLC. However, in patients with
LA-NSCLC treated with concurrent chemoradiation, the
proportion of PA volume that received more than 45–
60 Gy was associated with shorter OS [12].
The heart is known to be an important OAR for
patients receiving thoracic radiotherapy. Postoperative
radiation therapy for lung cancer was associated with
increased mortality from heart disease [13]. In the
RTOG 0617 trial, there were less than 5% cardiac
adverse events (≥ grade 3) in either the high dose or
low dose arm, and multivariate analysis showed that
the higher proportions of heart volume receiving ≥
5 Gy (H V5) or ≥ 30 Gy (H V30) were significantly
correlated with shorter survival [7]. However, Tucker
et al. [14] did not confirm the result of that trial re-
garding the impact of heart dose volume on OS.
In our previous study [12], the heart was not evaluated
in the univariate or multivariate analysis. In addition,
data from another independent research center is needed
to confirm these findings regarding the PA. Hence, we
performed a retrospective analysis to re-evaluate the re-
sults of the previous study and verify the impact of
dosimetric parameters of the PA and heart on the survival
of patients with NSCLC treated with definitive conven-
tional fractionated radiotherapy (CFRT) with or without
chemotherapy and to determine whether PA should
be considered an OAR and what PA dose/volume




We retrospectively reviewed the records of successive
patients with pathologically confirmed and medically in-
operable or unresectable stage I-IIIB NSCLC at Shengjing
Hospital between August 2010 and September 2014.
Patients who had good Karnofsky Performance Status
(KPS) (≥70), acceptable forced expiratory volume in 1 s
(FEV1) (>1.2 L) or FEV1% (>70%), and received the de-
finitive conventionally fractionated radiotherapy with
or without concurrent chemotherapy were included
in this study. Comorbidities, including hypertension,
cardiac-cerebral vascular disease, and chronic obstructive
pulmonary disease, were calculated by Charlson’s Comor-
bidity Index (CCI) [15, 16]. This study was approved by
the local ethics committee of our hospital. All patients
provided written informed consent prior to participating
in the study.
Radiotherapy parameter extraction
Radiotherapy was carried out using intensity modulated
radiation therapy (IMRT) or 3-dimensional conformal
radiatherapy (3DCRT) techniques. Targets contours
were defined as follows: gross tumor volume (GTV) in-
cluded primary lesion (GTVp) and metastatic lymph
nodes (GTVnd), which were either pathologically con-
firmed, had a short diameter ≥ 1 cm, or were PET posi-
tive; clinical target volume (CTV) was defined by GTVp
plus a 6–8 mm margin and the involved lymph node
region; planning target volume (PTV) was defined by
CTV plus a 0.5 cm margin for axial direction and a 1–
1.5 cm margin for head-foot direction. A total dose of
60–76 Gy in 30–38 fractions was delivered with 2.0 Gy
daily fractions over 6–7.5 weeks using 6 MV photons.
The prescribed dose covered 95% of the PTV. The dose
limits for the organs at risk (OAR) were as follows: bilateral
lung: V20 (percentage of volume receiving more than
20 Gy) ≤ 30% and mean lung dose (MLD) ≤ 20 Gy; spinal
cord: maximum dose of planning organ at risk volume
(PRV) ≤ 48–52 Gy; heart: V30 ≤ 40-60% and V40 ≤ 30-50%;
esophagus: V50 ≤ 50%. The PA and heart were contoured
according to Radiation Therapy Oncology Group (RTOG)
1106 atlas. Dosimetric parameters were extracted from the
treatment planning system (Oncentra, Elekta company,
Sweden), including mean and maximum doses to the heart
or PA as well as the percentage of PA or heart volume that
received a specific dose (from V5, 10, 15 to V70 every 5th
interval). The evaluation of the grades of PA invasion
included primary tumor and metastatic lymph nodes
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invading PA. PA invasion grade criteria were slightly
modified from those described previously [12] and are
summarized in Table 1. As per these modified criteria,
PA invasion was graded as 0, 1, 2, and 3 for no, minimal,
moderate, and extensive invasion, respectively.
Follow-up
All patients underwent follow up with chest CT scan
every 3 months during the first two years after radio-
therapy and every 6 months thereafter. In addition,
abdominal CT, bone Emission Computed Tomography
and brain Magnetic Resonance Imaging scans were per-
formed every 6 months or as clinically indicated. OS was
calculated from the start of radiotherapy until any cause
of death or the last date of follow-up. Patients still alive
at the last follow-up date (Sep 25, 2015) were censored
on that day, and loss to follow-up was considered as a
censored event. Progression-free survival (PFS) was
calculated from the start of radiotherapy until the first
imaging diagnosis of recurrent or progressive disease.
Local progression-free survival (LPFS) was based on re-
currence within the radiation field.
Statistical analyses
The potential prognostic factors for univariate analyses of
survival included patients characteristics, such as age;
gender; score of KPS, CCI; tumor associated factors, such
as tumor location, clinical stage, tumor (T) stage, lymph
nodal (N) stage, histologic type, and PA invasion grade;
treatment associated factors, such as treatment modality
(radiotherapy alone or sequential CRT or concurrent
CRT), radiotherapy technique (IMRT or 3DCRT), and RT
dose; as well as dosimetric parameters, such as minimum
dose for 95% volume of GTV, CTV and PTV (D95), the
percentage of PA volume (PA V5, 10, 15, and 20–70) and
heart volume (H V5, 10, and 15–70) that received a
specific radiation dose (Table 2). Pearson correlation coef-
ficient was used to examine the correlation between
potential prognostic factors. Survival was estimated using
the Kaplan-Meier method and curves were compared
using the log rank test. Both univariate and multivariate
analyses were performed to evaluate associations between
potential prognostic factors and OS. Multivariable Cox
proportional hazard models were used to calculate ad-
justed hazard ratios (HRs) and their 95% confidence inter-
vals (CIs); variables likely to be associated with OS, based
on P values of less than 0.1 from the univariate analysis,
were included in these models. Simultaneous inclusion in
the same multiple variable regression model of two highly
correlated variables (correlation co-efficient greater than
0.7) was considered inappropriate. Consequently, for mul-
tivariable analysis, such variables were entered separately,
one by one, with other independent variables. The optimal
cutoff points of significant continuous variables were
determined by Youden index in receiver operating charac-
teristic (ROC) analysis. Area under the curve (AUC)
determined by ROC analysis was used to estimate the pre-
dictive ability of covariates for survival status; cutoff values
were evaluated and confirmed by repeated Kaplan-Meier
and multivariate Cox analyses. The software of IBM SPSS
version 21.0 was used for statistical analysis, a P value less
than 0.05 was considered statistically significant.
Results
Characteristics of patients
One hundred forty-one patients with pathologically con-
firmed stage I-IIIB NSCLC were eligible for this study.
Patient characteristics are summarized in Table 2.
Correlation of potential prognostic factors
The correlations among clinicopathologic factors and
dosimetric parameters were calculated. RT dose was not
correlated with GTV, CTV and PTV; Pearson correlation
coefficients were 0.171, 0.121 and 0.064, respectively, all P
values were > 0.05. Both T stage and N stage were not
correlated with volumes of GTV, CTV or PTV or D95 to
target volumes, Pearson correlation coefficients ranged
from −0.126 to −0.291, all P values were > 0.05. In
addition, no correlations were noted between heart dosi-
metric parameters and target volumes (P > 0.05). Only
weak correlations were found between target volumes and
some PA dosimetric parameters (PA V35-60) and between
H V40-65 and PA V35-65, but all Pearson correlation
coefficients were less than 0.4, P < 0.05.
Results of univariate survival analysis
The median follow-up for the entire cohort was 16.9 months
(range: 6.5 to 42.0 months). Median PFS, LPFS, and OS
Table 1 Grading criteria of pulmonary artery invasiona
Grade Definition based on CT contrast
Grade 0 (no invasion) No evidence of vessel invasion,
≥1 mm from the closest pulmonary
vessel wall (presence of a fat plane
between tumor and vessel wall)
Grade 1 (minimal invasion) Tumor invasion with 0 mm to the
closest pulmonary vessel wall, no fat
plane, without presence of narrowing
or truncation of vessels, nor signs of
vessel wall damage (irregularity,
discontinuity or intra-luminal mass
formation)
Grade 2 (moderate invasion) Circumferential involvement with
narrowing or truncation
Grade 3 (extensive invasion) Tumor invading pulmonary vessel
extensively with any sign of vessel
wall damage: irregularity, discontinuity
or intra-luminal mass formation or
massive haemorrhage due to the
tumor invading pulmonary artery
aRevised from [12]
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Table 2 Clinicopathologic characteristic
Characteristic Number (%) Characteristic Number (%)
Age (years) RT modality
Median (range) 60 (39–85) RT alone 55 (39%)
< 60 72 (5.1) concurrent CRT 47 (33.3%)
≥ 60 69 (48.9) sequential CRT 39 (27.7%)
Gender Tumor stage
Male 97 (68.8%) T1 26 (18.4%)
Female 44 (31.2%) T2 46 (32.6%)
KPS (70–100) T3 38 (27%)
70–80 5 (3.5%) T4 31 (22%)
80–90 28 (19.9%) Lymph nodes stage
90–100 108 (76.6) N0 42(29.8%)
Smoking N1 48 (34%)
No 68 (48.2%) N2 32 (22.7%)
Yes 73 (51.8%) N3 19 (13.5%)
Weight loss (%) Clinical stage
Median (range) 3 (0–10) I 5 (3.5%)
≤ 3% 72 (51.1) II 47 (33.3%)
> 3%-10% 69 (48.9) IIIA 62 (44%)
COPD IIIB 27 (19.1%)
No 130 (92.2%) PA invasion grade
Yes 11 (7.8%) Grade 0 49(34.8%)
CVD Grade 1 36(25.5%)
No 108 (76.6%) Grade 2 37(26.2%)
Yes 33 (23.4%) Grade 3 19(13.5%)
Hypertension Target volume (cc)
median (range)
No 109 (77.3%)
Yes 32 (22.7%) GTV 43.6 (9–400.9)
CCI CTV 92.2 (12.56–843.6)
Median (range) 3 (0–7) PTV 213.7 (23.5–1025.5)
< 3 62 (44.0%) D95 to targets (Gy)
median (range)
≥ 3 79 (56.0%)
Tumor location D95 to GTV 64.9 (48.1–74.0)
Central 116 (82.3%) D95 to CTV 63.1 (46.4–71.9)
Peripheral 25 (17.7%) D95 to PTV 60.1 (45.6–69.9)
Pathology Dmax to PA (Gy)
Adenocarcinoma 71 (50.3%) Median (range) 65.8 (0.6–76.2)
Squamous 61 (43.3%) Dmean to PA (Gy)
Large-cell & NOS 9 (6.4%) Median (range) 37.9 (0–71.3)
RT technique Dmax to Heart (Gy)
IMRT 52 (36.9%) Median (range) 56 (0.2–65.7)
3DCRT 89 (63.1%) Dmean to Heart (Gy)
RT dose (Gy) Median (range) 5.2 (0–34.9)
Median (range) 66 (60–76)
< 66 62 (44.0%)
≥ 66 79 (56.0%)
KPS Karnofsky performance status, COPD chronic obstructive pulmonary disease, CVD Cardiac vascular disease, CCI Charlson comorbidity index, NOS NSCLC not
otherwise specified, IMRT intensity modulated radiation therapy, 3DCRT three-dimensional conformal radiation therapy, RT radiotherapy, Chemo Chemotherapy,
GTV gross tumor volume, CTV clinical target volume, PTV planning target volume, D95 minimum dose to 95% volume of targets, PA pulmonary artery, cc cubic
centimeter, Gy gray, Dmax Maximum dose, Dmean Mean dose
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were 8.4 months, 12.4 months, and 20.5 months (95% CI:
9.58-31.42 months), respectively, and the 1-, 2- and 3-year
OS rates were 75.9%, 58.2% and 56%, respectively (Fig. 1).
Univariate analysis showed that age, gender, status of
smoking, weight loss, tumor location, treatment mo-
dality, RT dose, D95 to target volumes, maximum and
mean dose to the PA or heart were not related with
OS. However, KPS score, T stage, N stage, clinical
stage, CCI, PA invasion grade, GTV, CTV, PTV, PA
V20, 25–65 and H V30, 35–45 were significantly asso-
ciated with median OS (P < 0.1) (Table 3).
Results of multivariate survival analysis
Multivariate analysis indicated that the clinicopathologic
factors significantly associated with shorter OS were
lower KPS score (< 85), higher CCI (≥ 3), higher T
(T3, T4) stage, N (N2, N3) stage, and higher grade of
PA invasion. Median OS was 13.1 months vs.
32.7 months in patients with KPS < 85 vs. ≥ 85, re-
spectively; was 10.9 months vs. 37.9 months in CCI ≥ 3
vs. < 3, respectively; was 13.5 months vs. 41.8 months
in T3, 4 stage vs. T1, 2 stage, respectively; and was
19.3 months vs. 27.8 months in N2, 3 stage vs. N0, 1 stage,
respectively. All P values were less than 0.05. In addition,
the median OS and 2-year survival rates were 41.8 months
and 79.6%, 27.8 months and 66.67%, 12.7 months and
37.84%, and 7.5 months and zero, respectively, for no in-
vasion (grade 0), minimal (grade 1), moderate (grade 2),
and extensive invasion (grade 3), P < 0.05 (Fig. 2 and
table 4). Two patients with grade 3 PA invasion (2/19,
10.5%) died of massive bleeding after radiotherapy, and no
other bleeding events or rupture of great vessel were ob-
served during or after radiotherapy.
With regard to dosimetric factors, multivariate analysis
demonstrated that volumes of targets including GTV,
CTV, PTV and the percentages of heart volume that
received a specific radiation dose, were not significantly
associated with OS. However, PA V40-55 Gy were
significantly associated with OS independent of KPS and
stage. According to the ROC curves, the best cutoff
values for PA V40, 45, 50 and 55 predictive of OS were
80%, 68%, 45%, and 32%, respectively. Median OS rates
were 14 months vs. 27.8 months, respectively in patients
with PA V40 ≥ 86% vs. < 86%, P < 0.0001; were
13.5 months vs. 37.9 months, respectively in patients
with PA V45 ≥ 68% vs. < 68%, P < 0.0001; were
14.2 months vs. 32.7 months, respectively in patients
with PA V50 ≥ 45% vs. < 45%, P < 0.0001; and were
10.9 months vs. 41.8 months, respectively in patients
with PA V55 ≥ 32% vs. < 32%, P < 0.0001 (Fig. 3a-d). The
dose volume histograms (DVH) and dose-curves of four
patients presenting with high grades of PA invasion and
PA V40-55 are shown in Fig. 4a-d.
Discussion
The present study demonstrated that the score of KPS,
CCI, stages of T and N, PA invasion grade, as well as
percentage of PA volumes that received 40–55 Gy were
independent prognostic factors of OS for patients with
NSCLC treated with definitive CFRT. PA invasion grade
was significantly associated with OS, though it was not
associated with bleeding during or after radiotherapy. In
Fig. 1 Curve of overall survival (OS)
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addition, patients with PA V40 > 80%, V45 > 68%, V50 >
45% or V55 > 32% had a significantly shorter OS. The re-
sults further confirmed our previous conclusions [12]
and suggested that the PA should be regarded as an
OAR during conventionally fractionated thoracic radio-
therapy or chemoradiotherapy, and that the grade of PA
invasion and PA dosimetric parameters V40-55 could be
used to predict survival for those patients with NSCLC
who received definitive CFRT.
Radiation induced lung injury, esophagitis, and heart
injuries are the most frequent radiation related toxic-
ities and have been widely investigated recently. The
RTOG 0617 trial [7] revealed that high dose radiother-
apy given to patients with LA-NSCLC failed to im-
prove local control and prolong OS compared with
standard dose radiotherapy. The possible damage to
the local immune microenvironment of the field
receiving high dose radiation, and the radiation related
toxicities might be the major reason why patients with
high dose radiotherapy had shorter survival. In this
trial, H V5 and H V30, but not radiation modalities
were correlated with OS [7]; The present study also
evaluated the relationship between OS and heart dosi-
metric parameters including maximum or mean dose
to the heart, or the percentage of heart volume that
received a specific dose (H V5-70). However, no
significant associations were found between them,
although the radiation related heart injury was not
evaluated herein. The reason for this finding might be
attributed to relatively strict radiation dose constraints
for heart that were used in our study. Our results were
in accordance with Tucker et al’s study [14], which
found that heart dosimetric parameters did not signifi-
cantly affect survival.
Table 3 The result of multivariate analysis of significative potential prognostic factors associated with overall survival by using
univariate analysis
Univariate Multivariate
Variables P value P value HR 95% CI
Categorical Variables CCI 0.00001 0.00001 1.816 1.386–2.378
T-stage 0.0004 0.0001 3.160 1.944–5.138
N-stage 0.007 0.001 1.907 1.315–2.767
Clinical stage 0.001 0.493 0.697 0.248–1.96
PA invasion grade 0.028 0.0001 2.172 1.467–3.216
Continuous Variables KPS 0.001 0.043 0.934 0.886–0.936
GTV 0.015 0.066 0.986 0.975–0.997
CTV 0.045 0.07 1.01 1.003–1.017
PTV 0.081 0.203 0.998 0.995–1.001
PA V10 0.099 0.698 0.275 0–16.913
PA V15 0.098 0.792 0.309 0–15.602
PA V20 0.084 0.678 1.691 0–4.357
PA V25 0.094 0.468 0.022 0–6.387
PA V30 0.002 0.553 8.474 0.007–9.855
PA V35 0.001 0.111 2.367 0.271–2.967
PA V40 0.001 0.043 2.113 1.014–4.936
PA V45 0.0004 0.0001 2.660 1.089–5.717
PA V50 0.001 0.0001 1.203 0.062–2.056
PA V55 0.002 0.05 1.489 0.098–2.096
PA V60 0.005 0.191 0.076 0.002–3.621
PA V65 0.027 0.149 0.069 0.002–2.598
H V30 0.062 0.148 0 0–4.075
H V35 0.059 0.227 1.725 0–9.681
H V40 0.035 0.755 0.001 0–5.625
H V45 0.092 0.923 5.765 0–12.916
CCI Charlson comorbidity index, KPS karnofsky performance status, GTV gross tumor volume, CTV clinical target volume, PTV planning target volume, D95
minimum dose to 95% volume of targets, PA pulmonary artery, PA V5, 10–70: the percentage of PA volume receiving 5,10 to 70Gy, PAmax the maximum dose to
PA, PAmean the mean dose to PA, H V5,10-75: the percentage of heart volume receiving 5, 10 to 70Gy, Hmax the maximum dose to heart, Hmean the mean dose
to heart
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A great vessel is deemed as a dose-limiting organ
when lesions are given hypofractionated or stereotactic
body radiotherapy (SBRT) [17]. Some researchers
thought there were greater risks of severe hemoptysis
and early mortality among patients who had severe PA
invasion during or after radiotherapy. A previous study
stated that vessel rupture may result from the penetra-
tion of the tumor into the vessel wall itself [18]. How-
ever, a later study [19] showed that this explanation
might be implausible because penetration of a tumor
into the wall of an elastic artery is so unusual except in
the following circumstances: the vessel itself (e.g.,
atherosclerosis), had exposed vasa vasorum during
surgery and damage to the adventitia caused by ulcer,
fistulas or infection around artery that were independent
of radiotherapy [19]. Another study showed that toxicity
to the aorta after reirradiation was relatively rare, even
when maximum composite doses to the aorta exceeded
100 Gy [20].
Recently, our study [12] first proposed grading criteria
for PA invasion from grade 0 to grade 5, describing the
distance of tumor to the PA, degree of circumferential
involvement of the PA, and status of vessel wall damage.
In that study, we found patients with PA invasion of
grade 0–1 had a longer median OS than those with
grade 2–5 (33.4 months vs. 18.3 months, P = 0.242), and
two of the 4 patients with grade 5 PA invasion died sud-
denly from massive hemorrhage at 3 and 4.5 months
after completion of radiotherapy. To facilitate its clinical
use, we simplified the grading system to grade 0, 1, 2, 3
for no, minimal, moderate, and extensive invasion, re-
spectively. In this group of patients, we found a signifi-
cant relationship between grade of PA invasion and
survival. Two patients with extensive PA invasion died
of massive bleeding after radiotherapy. We believe that a
higher grade of PA invasion indicates worse clinicopatho-
logic behavior and prognosis, though few bleeding events
were observed during or after radiotherapy in both studies.
Fig. 2 Curve of overall survival (OS) by pulmonary artery (PA) invasion grade: grade 1 (no invasion), grade 2 (minimal invasion), grade 3
(moderate invasion), and grade 4 (extensive invasion)
Table 4 Overall survival (OS) of different grade of PA invasion
Grade n Median OS (95%CI) (months)* 1-year OS rate (%) 2-year OS rate (%)
0 49 41.8 (−) 100 79.6
1 36 27.8 (19.96–32.36) 91.67 66.67
2 37 12.7 (9.85–15.56) 54.05 37.84
3 19 7.5 (5.25–9.75) 21.05 0
*P = 0.0003 for trend
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In the future, reliable imaging or pathological assessment of
great vessel rupture needs to be developed to confirm this
assumption.
The present study also found that the percentages of
PA volume that received 40–55 Gy were significantly
associated with OS regardless of target volume, KPS,
CCI and stage. Especially, patients with PA V45 > 68%,
and those with PA V55 > 32% had a significantly shorter
OS. Interestingly, the results were highly consistent with
our previous study in which high dose volume of PA
V45-60 was predictive of shorter OS, and the cut-off
values of PAV45 and V60 were 70% and 37%, respectively.
Both studies suggest that PA V45 (68-70%) is a better
cut-off value predictive of shorter OS in patients with
LA-NSCLC treated with CFRT. Our findings differed
from those using SBRT, in which maximum dose
exceeding 50 Gy to the PA was related with massive
hemoptysis and caused death [21]; in our study, when
CFRT was administrated, the maximum dose to the
PA was not related with OS.
In the present study, we found that GTV, CTV, PTV
and dose coverage of target volumes were not associ-
ated with OS, which seemed contradictory to the
effect of the factors T or N stage on OS, because a
higher T or N stage often results in a larger target
volume. However, we did not see any correlation be-
tween T or N stage and the target volumes GTV, CTV
or PTV. Correlation analysis revealed only weak corre-
lations between target volumes and PA V40-V55, thus
ruling out an influence of target volume on PA volume
dose. Certainly, our study may be too small to distin-
guish the independent or synthetic effect of heart and
PA dosimetric parameters on survival. Future pro-
spective studies with larger numbers of patients are
needed to pursue the combined effects of heart and
PA dosimetry. In addition, in our study only two patients
with extensive PA invasion died of fatal hemoptysis after
radiotherapy during follow-up. Hence, it appears that
in this cohort, these rare outcomes, such as fatal
hemoptysis or massive bleeding, are not good end
Fig. 3 Survival curves by the percentage of PA volume that received 40-55Gy. (a) PA V40≥ 86% vs. < 86%; (b) PA V45≥ 68% vs. < 68%; (c) PA
V50≥ 45% vs. < 45% and (d) PA V55≥ 32% vs. < 32%
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points guide recommendations for dosimetric con-
straints for this OAR. PA grading variation from the
start of radiotherapy to death may be an alternative
end point. However, this is not evaluated in the
present study because the accurate PA grading vari-
ation largely depends on reliable imaging or patho-
logical analysis of abnormalities, such as ulcer, fistula,
and stricture. On the other hand, we believe that the
PA is an OAR similar to the heart, and that higher
dose-volume irradiation to the PA might also cause
serious consequences such as pericarditis, arrhythmia,
and fatal hemoptysis. Future studies are needed to
validate these postulations.
Conclusion
PA invasion grade and PA V40-55 were independent
factors predictive of OS regardless of KPS, CCI and stage
in patients with NSCLC treated with definitive CFRT.
We proposed that the PA should be regarded as an
organ at risk relevant to target delineation and dose
limitation during CFRT. Limiting moderate-to-high PA
dose volume, especially PA V45, is recommended due to
its better ability to predict survival.
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PFS: Progression-free survival; PRV: Planning organ at risk volume;
PTV: Planning target volume; ROC: Receiver operating characteristic;
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